Stock Price & Analysis

The S1 support level for FENC Stock is $6.02 ,The R1 resistant level for FENC Stock is $7.02.

As of the end of day on 2025-03-11, the price of FENC Stock was $6.305.

The target price for FENC Stock according to analyst rating is 13.00, with the highest price target at 13.00 and the lowest at 13.00. Analysts have a Moderate Buy rating on FENC Stock overall.

The market cap of FENC is $168.2M.

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

FENC has a total of 29 employees.